TN

Tetsuya Nakatsura

NC National Cancer Center: 4 patents #41 of 486Top 9%
YU Yamaguchi University: 3 patents #15 of 132Top 15%
OS Oncotherapy Science: 2 patents #36 of 80Top 45%
KU Kyoto University: 1 patents #568 of 1,688Top 35%
LS Lsip: 1 patents #3 of 30Top 10%
KO Kanagawa Prefectural Hospital Organization: 1 patents #8 of 20Top 40%
NJ National Cancer Center Japan: 1 patents #6 of 17Top 40%
TL Takeda Pharmaceutical Company Limited: 1 patents #859 of 1,531Top 60%
MC Medinet Co.: 1 patents #7 of 26Top 30%
KF Kumamoto Technology & Industry Foundation: 1 patents #3 of 8Top 40%
KU Kumamoto University: 1 patents #5 of 44Top 15%
📍 Kashiwa, JP: #115 of 653 inventorsTop 20%
Overall (All Time): #445,323 of 4,157,543Top 15%
11
Patents All Time

Issued Patents All Time

Showing 1–11 of 11 patents

Patent #TitleCo-InventorsDate
12129291 Anti-GPC3 antibody Koji Tamada, Yukimi Sakoda, Keigo Saito 2024-10-29
11718663 Anti-GPC3 antibody Koji Tamada, Yukimi Sakoda, Keigo Saito 2023-08-08
11603519 T-cell receptor Toshiaki Yoshikawa, Yasushi UEMURA, Kyoko FUKUDA, Shin KANEKO, Atsutaka Minagawa +2 more 2023-03-14
10781249 Anti-GPC3 antibody Koji Tamada, Yukimi Sakoda, Keigo Saito 2020-09-22
9505824 Antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation Tetsuro Sasada, Kazuya Ofuji 2016-11-29
9465030 Kit for diagnosing malignant melanoma Keigo Saito 2016-10-11
9404925 Cancer antigen and use thereof Yasuharu Nishimura 2016-08-02
8535942 Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same Yasuharu Nishimura, Hiroyuki Komori 2013-09-17
8053556 Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same Yasuharu Nishimura, Hiroyuki Komori 2011-11-08
8017345 Diagnostic kit for malignant melanoma Yasuharu Nishimura, Yoshiaki Ikuta 2011-09-13
7803533 Diagnostic agent for malignant melanoma Yasuharu Nishimura 2010-09-28